Dihydro-1[1H]-quinolin-2-one derivatives as RXR agonists for...

Details Dihydro-1[1H]-quinolin-2-one derivatives as RXR agonists for... Dihydro-1[1H]-quinolin-2-one derivatives as RXR agonists for...

2006-09-25

2009-12-29

Shameem, Golam M (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S112000, C546S152000, C546S153000, C546S157000, C514S299000, C514S311000

Reexamination Certificate

active

07638533

ABSTRACT:
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating RXR mediated disorders. More particularly, the compounds of the present invention are RXR agonists useful for treating RXR mediated disorders.

REFERENCES:
patent: 5739338 (1998-04-01), Beard et al.
patent: 6048873 (2000-04-01), Vasudevan et al.
patent: 6734193 (2004-05-01), Duong et al.
patent: 7071218 (2006-07-01), Pfahl et al.
patent: 7196108 (2007-03-01), Pfahl et al.
patent: 7265139 (2007-09-01), Tachdjian et al.
patent: 1117648 (2003-08-01), None
Unger, R.H., “Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes.”Diabetologia, 1985, vol. 28, pp. 119-121.
Rossetti, L. et al., “Glucose Toxicity”Diabetes Care, 1990, vol. 13, pp. 610-630, No. 6.
Mangelsdorf, D.J. et al., “The RXR Heterodimers and Orphan Receptors.”Cell, 1995, vol. 83, pp. 841-850.
Kastner, P. et al., “Nonsteroid Nudear Receptors: What are Genetic Studies Telling Us about Their Role in Real Life”?Cell, 1995, vol. 83, pp. 859-869.
Hibi, S. et al.: “Syntheses and Structure-Activity Relationships of Novel Retinoid X Receptor”.Journal of Medicinal Chemistry, American Chemical Society, 1998, vol. 41, No. 17, Aug. 13, pp. 3245-3252, XP002131548, ISSN:0022-2623.
Haffner, C.D. et al: “Structure-Based Design of Potent Retinoid X Receptor a Agonists”.Journal of Medicinal Chemistry, 2004, 47(8), 2010-2029 Coden: JMCMAR; ISSN:0022-2623, XP002415204.
Pogenberg, V. et al.: “Characterization of the Interaction between Retinoic Acid Receptor/Retinoid X Receptor (RAR.RXR) Heterodimers and Transcriptional Coactivators through Structural and Fluorescence Anisotropy Studies”.Journal of Biological Chemistry, 2005, vol. 280(2), 1625-1633 Coden: JBCHA3; ISSN:0021-9258, XP002415142.
PCT International Search Report No. PCT/US2006/037545 dated May 23, 2007 which relates to U.S. Appl. No. 11/534,928.
Denmark et al., “Cyclopropanation with Diazomethane and Bis(oxazoline)palladium(II) Complexes.”, Journal of Organic Chemistry, 1997, vol. 62(10), pp. 3375-3389.
Charette et al., “Bis(oxazoline)•copper(I)-catalyzed enantioselective cyclopropanation of cinnamate esters with diazomethane.”, Tetrahedron: Asymmetry, 2003, vol. 14(7), pp. 867-872.
Eilbracht et al., Tandem silylformylation/Wittig Olefination of Terminal Alkynes: Stereoselective Synthesis of 2,4-Dienoic Esters., European Journal of Organic Chemistry, 2000(7), pp. 1131-1135.

Affiliated with

Also associated with

Rating

Dihydro-1[1H]-quinolin-2-one derivatives as RXR agonists for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dihydro-1[1H]-quinolin-2-one derivatives as RXR agonists for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydro-1[1H]-quinolin-2-one derivatives as RXR agonists for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4147478